Cure Pharmaceutical Holding Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.11
- Today's High:
- $0.11
- Open Price:
- $0.11
- 52W Low:
- $0.081
- 52W High:
- $0.425
- Prev. Close:
- $0.11
- Volume:
- 0
Company Statistics
- Market Cap.:
- $8.99 million
- Book Value:
- -0.002
- Revenue TTM:
- $5.86 million
- Operating Margin TTM:
- -208.84%
- Gross Profit TTM:
- $4.38 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -26.91%
- Return on Equity TTM:
- -246.81%
Company Profile
Cure Pharmaceutical Holding Corp had its IPO on under the ticker symbol CURR.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Cure Pharmaceutical Holding Corp has a staff strength of 28 employees.
Stock update
Shares of Cure Pharmaceutical Holding Corp opened at $0.11 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.11 - $0.11, and closed at $0.11.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Cure Pharmaceutical Holding Corp have slipped by -8.33%.
Cure Pharmaceutical Holding Corp's Key Ratios
Cure Pharmaceutical Holding Corp has a market cap of $8.99 million, indicating a price to book ratio of 3.8469 and a price to sales ratio of 1.8358.
In the last 12-months Cure Pharmaceutical Holding Corp’s revenue was $5.86 million with a gross profit of $4.38 million and an EBITDA of $-8980000. The EBITDA ratio measures Cure Pharmaceutical Holding Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cure Pharmaceutical Holding Corp’s operating margin was -208.84% while its return on assets stood at -26.91% with a return of equity of -246.81%.
In Q3, Cure Pharmaceutical Holding Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 32.1%.
Cure Pharmaceutical Holding Corp’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cure Pharmaceutical Holding Corp’s profitability.
Cure Pharmaceutical Holding Corp stock is trading at a EV to sales ratio of 2.9074 and a EV to EBITDA ratio of -1.1665. Its price to sales ratio in the trailing 12-months stood at 1.8358.
Cure Pharmaceutical Holding Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $14.96 million
- Total Liabilities
- $15.06 million
- Operating Cash Flow
- $13.89 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Cure Pharmaceutical Holding Corp ended 2024 with $14.96 million in total assets and $0 in total liabilities. Its intangible assets were valued at $14.96 million while shareholder equity stood at $-173000.00.
Cure Pharmaceutical Holding Corp ended 2024 with $0 in deferred long-term liabilities, $15.06 million in other current liabilities, 71000.00 in common stock, $-112809000.00 in retained earnings and $4.69 million in goodwill. Its cash balance stood at $4.44 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Cure Pharmaceutical Holding Corp’s total current assets stands at $8.25 million while long-term investments were $216000.00 and short-term investments were $0. Its net receivables were $2.66 million compared to accounts payable of $1.63 million and inventory worth $640000.00.
In 2024, Cure Pharmaceutical Holding Corp's operating cash flow was $13.89 million while its capital expenditure stood at $0.
Comparatively, Cure Pharmaceutical Holding Corp paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.11
- 52-Week High
- $0.425
- 52-Week Low
- $0.081
- Analyst Target Price
- $
Cure Pharmaceutical Holding Corp stock is currently trading at $0.11 per share. It touched a 52-week high of $0.425 and a 52-week low of $0.425. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.1 and 200-day moving average was $0.14 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 3037.8% of the company’s stock are held by insiders while 24.2% are held by institutions.
Frequently Asked Questions About Cure Pharmaceutical Holding Corp
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Avenir Wellness Solutions, Inc., a wellness platform technology company, which develops proprietary wellness, nutraceutical, and topical delivery systems. The company’s pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; CUREfilm Canna, a cannabinoid product with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data; and CUREfilm Central Nervous System, a novel dosage form to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety. It also sells various wellness products under its distribution partners’ brands. In addition, the company develops 50,000IU and Vitamin D3 OTF for oral administration. It has a licensing agreement with Canopy Growth Corporation. The company was formerly known as CURE Pharmaceutical Holding Corp. and changed its name to Avenir Wellness Solutions, Inc. in January 2023. Avenir Wellness Solutions, Inc. was founded in 2011 and is headquartered in Sherman Oaks, California.